Results 81 to 90 of about 16,170 (204)

A Response to ‘Reply to: Superficial Pustular Folliculitis of the Face and Neck—A Non‐Infectious Eruption Responding to Topical Steroids’

open access: yes
JEADV Clinical Practice, EarlyView.
Hui‐Peng Huang   +4 more
wiley   +1 more source

Efficacy and Safety of Anti‐IL‐4Rα Stapokibart in Elderly Patients With Moderate‐To‐Severe Atopic Dermatitis

open access: yesInternational Journal of Dermatology, EarlyView.
ABSTRACT Background Elderly patients with moderate‐to‐severe atopic dermatitis (AD) often exhibit more heterogeneous inflammatory profiles compared with younger adults. To evaluate the efficacy and safety of stapokibart, an anti‐interleukin‐4 receptor α subunit (IL‐4Rα) monoclonal antibody, in different age subgroups.
Yan Zhao   +26 more
wiley   +1 more source

Efficacy and Safety of Oral Icotrokinra in Moderate‐to‐Severe Plaque Psoriasis: A Systematic Review, Meta‐Analysis, and Trial Sequential Analysis

open access: yesInternational Journal of Dermatology, EarlyView.
Meta‐analysis of randomized controlled trials demonstrates that oral icotrokinra significantly improves PASI responses in patients with moderate‐to‐severe plaque psoriasis, with early clinical benefit and a placebo‐comparable safety profile, supported by trial sequential analysis confirming robust and sufficient evidence.
Alhasan Altayf   +5 more
wiley   +1 more source

Deep and disseminated dermatophytosis in immunocompromised populations—A systematic review

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Dermatophyte infections of the dermis and subcutaneous tissue (i.e. deep dermatophytosis)—associated with secondary complications including pseudomycetoma and systemic dissemination—affect vulnerable populations with primary or acquired immunodeficiencies.
Aditya K. Gupta   +5 more
wiley   +1 more source

Efficacy and safety of brodalumab in palmoplantar pustulosis: A 68‐week randomized Phase 3 trial

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
This open‐label study is a continuation of the 16‐week double‐blind, Phase 3 trial assessing the efficacy and safety of brodalumab 210 mg subcutaneously, till a 68‐week extension period. Continued improvement was seen in the PPPASI 50/75/90 responses, PPPSI scores, PGA 0/1 responses and DLQI. Abstract Background The efficacy and safety of brodalumab in
Masamoto Murakami   +6 more
wiley   +1 more source

Delphi consensus: First‐line use of biologics and small molecules in hidradenitis suppurativa

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
This Delphi Consensus study identified upgrade criteria for the use of biologics and small molecules as first‐line therapy in hidradenitis suppurativa (HS). European HS experts evaluated 16 clinical scenarios, voting on eligibility for therapy escalation.
Georgios Nikolakis   +54 more
wiley   +1 more source

Incorporating the Competencies of Evidence‐Based Veterinary Medicine Focused on Pharmacotherapeutics Into Clinical Rotations for Small Animal Dermatology and Food Animal Medicine and Surgery at a Veterinary Medical Teaching Hospital in the US

open access: yesJournal of Veterinary Pharmacology and Therapeutics, EarlyView.
ABSTRACT Building the skills and knowledge necessary to practice evidence‐based veterinary medicine (EBVM) should occur throughout the veterinary curriculum. Operationalizing EBVM includes asking a clinical question in PICO format, searching the biomedical literature for evidence, critically appraising the evidence, and applying the evidence to make a ...
Virginia R. Fajt   +4 more
wiley   +1 more source

Dermatologic Findings of RELA‐Associated Autoinflammatory Disease

open access: yesPediatric Dermatology, EarlyView.
ABSTRACT Variants in the gene RELA have been implicated in a monogenic, hereditary form of Behcet's‐like syndrome. This case series describes the dermatologic manifestations of three patients with identified RELA‐associated autoinflammatory disease.
Elizabeth Nourse   +4 more
wiley   +1 more source

Dermatological Adverse Events Associated With Lapatinib Treatment in Dogs With Urothelial Carcinoma: A Retrospective Study

open access: yesVeterinary Dermatology, EarlyView.
Lapatinib is widely used in human oncology; however, dermatological adverse events (DAEs) are common and have been correlated with treatment efficacy. In veterinary medicine, lapatinib use in combination with piroxicam has been shown to be effective in treating canine urothelial carcinoma (UC); however, the incidence and prognostic significance of DAEs
Kosuke Horita   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy